|
Video: What is a Stock Split?
|
|
CymaBay Therapeutics is a clinical-stage biopharmaceutical company focused on developing and providing access to therapies for patients with liver and other chronic diseases. Co.'s pipeline includes the following clinical stage product candidates: seladelpar, a selective agonist for the peroxisome proliferator-activated receptor delta, which is a nuclear receptor that regulates genes involved in bile acid/sterol, lipid, and glucose metabolism, and regulation of certain inflammatory cells; and MBX-2982, which targets G protein-coupled receptor 119 (GPR119), a receptor that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion. According to our CBAY split history records, CymaBay Therapeutics has had 0 splits. | |
|
CymaBay Therapeutics (CBAY) has 0 splits in our CBAY split history database.
Looking at the CBAY split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into CymaBay Therapeutics shares, starting with a $10,000 purchase of CBAY, presented on a split-history-adjusted basis factoring in the complete CBAY split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
04/01/2014 |
|
End date: |
03/22/2024 |
|
Start price/share: |
$8.00 |
|
End price/share: |
$32.48 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
306.00% |
|
Average Annual Total Return: |
15.07% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$40,593.08 |
|
Years: |
9.98 |
|
|
|
|
|